medium size polysulfone cartridges (FiberCell Systems)
FiberCell Systems is a verified supplier 
FiberCell Systems manufactures this product 
96
Structured Review
FiberCell Systems
medium size polysulfone cartridges
Medium Size Polysulfone Cartridges, supplied by FiberCell Systems, used in various techniques. Bioz Stars score: 96/100, based on 391 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/medium+20kd+mwco+ps+cartridge/Medium+20kd+MWCO+PS+Cartridge/pmc13049661-52-0-4
Average 96 stars, based on 391 article reviews
Medium Size Polysulfone Cartridges, supplied by FiberCell Systems, used in various techniques. Bioz Stars score: 96/100, based on 391 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/medium+20kd+mwco+ps+cartridge/Medium+20kd+MWCO+PS+Cartridge/pmc13049661-52-0-4
Average 96 stars, based on 391 article reviews
medium size polysulfone cartridges - by Bioz Stars,
2026-09
96/100 stars
Images
1) Product Images from "An assay toolkit for anti-tuberculosis drugs in the hollow fiber system"
Article Title: An assay toolkit for anti-tuberculosis drugs in the hollow fiber system
Journal: iScience
doi: 10.1016/j.isci.2026.115292
Figure Legend Snippet: Drug-fiber compatibility tests of ethambutol and linezolid in the HFS-TB Expected (dashed line) and observed (solid lines) pharmacokinetic (PK) profiles of (a) ethambutol and (b) linezolid, sampled from the intra-capillary space (ICS; green line) and extra-capillary space (ECS; purple line) of polysulfone (PS), polyvinylidene fluoride (PVDF), and cellulose cartridges. Targeted PK parameters for each antibiotic are described in . Drug concentration values are provided in . EMB, ethambutol, LZD, linezolid.
Techniques Used: Concentration Assay
Figure Legend Snippet: Drug-fiber compatibility tests of isoniazid, clarithromycin, moxifloxacin, rifampicin and rifapentine in the HFS-TB Expected (dashed line) and observed (solid lines) pharmacokinetic (PK) profiles of (a) isoniazid, (b) clarithromycin, (c) moxifloxacin, (d) rifampicin, and (e) rifapentine, sampled from the intra-capillary space (ICS; green line) and extra-capillary space (ECS; purple line) of polysulfone (PS), polyvinylidene fluoride (PVDF), and cellulose cartridges. Targeted PK parameters for each antibiotic are described in . Drug concentration values are provided in . CLA, clarithromycin; INH, isoniazid; MXF, moxifloxacin; RMP, rifampicin; RPT, rifapentine.
Techniques Used: Concentration Assay
Figure Legend Snippet: Drug-fiber compatibility tests of pretomanid, delamanid, and bedaquiline in the HFS-TB Expected (dashed line) and observed (solid lines) pharmacokinetic (PK) profiles of (a) pretomanid, (b) delamanid, and (c) bedaquiline, sampled from the intra-capillary space (ICS; green line) and extra-capillary space (ECS; purple line) of polysulfone (PS), polyvinylidene fluoride (PVDF), and cellulose cartridges. Targeted PK parameters for each antibiotic are described in . Drug concentration values are provided in . BDQ, bedaquiline; DLM, delamanid; PTD, pretomanid.
Techniques Used: Concentration Assay
Figure Legend Snippet: Optimization approach to use bedaquiline in the HFS-TB Observed pharmacokinetic (PK) profiles of bedaquiline, sampled from the extra-capillary space (ECS) of polysulfone (PS), polyvinylidene fluoride (PVDF), and cellulose HFS-TB cartridges. The targeted median concentration at protein-unbound steady state in the lung (C med, ss = 0.061 μg/mL) is indicated in and represented in the graphs by a dashed line. Drug concentration values are provided in . BDQ, bedaquiline.
Techniques Used: Concentration Assay
Related Articles
Hood:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic In Vitro:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic Activity Assay:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic Bacteria:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic Molecular Weight:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic Cell Culture:Article Title: Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study Article Snippet: ). The HFIM was assembled as previously described ( 27 ). In brief, for each dosing regimen, two HFIM circuits were performed per isolate using FibreCell Systems cellulosic |
